SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-6.16%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$605M
AUM Growth
+$605M
(-8.3%)
Cap. Flow
-$4.4M
Cap. Flow
% of AUM
-0.73%
Top 10 Holdings %
Top 10 Hldgs %
49.83%
Holding
105
New
20
Increased
23
Reduced
13
Closed
26
Top Buys
| 1 |
Sanofi
SNY
|
$32.4M |
| 2 |
Novo Nordisk
NVO
|
$23.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$15.3M |
| 4 |
Gilead Sciences
GILD
|
$13M |
| 5 |
PTC Therapeutics
PTCT
|
$10.5M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$31.8M |
| 2 |
GSK
GSK
|
$20M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.8M |
| 4 |
Verint Systems
VRNT
|
$12.8M |
| 5 |
BLUE
bluebird bio
BLUE
|
$9.54M |
Sector Composition
| 1 | Healthcare | 79.34% |
| 2 | Technology | 12.65% |
| 3 | Industrials | 2.41% |
| 4 | Consumer Discretionary | 1.28% |
| 5 | Communication Services | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $56.3M | 8.69% | 1,109,900 +180,000 | +19% | +$9.13M |
|
2
Johnson & Johnson
JNJ
$427B
| $51.8M | 7.99% | 400,000 | – | – |
|
3
Merck
MRK
$210B
| $39.6M | 6.11% | 470,000 +18,000 | +4% | +$1.52M |
|
|
4
Sanofi
SNY
$121B
| $32.4M | 5.01% | +700,000 | New | +$32.4M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $24.8M | 3.84% | 250,000 | – | – |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $23.5M | 3.63% | 2,930,320 +420,000 | +17% | +$3.37M |
|
|
7
Novo Nordisk
NVO
$251B
| $23.3M | 3.59% | +450,000 | New | +$23.3M |
|
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $18.7M | 2.89% | 248,038 +203,038 | +451% | +$15.3M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $16.2M | 2.51% | 165,713 -171,087 | -51% | -$16.8M |
|
|
ARQL
10
DELISTED
Arqule Inc
ARQL
| $14.9M | 2.31% | 2,082,643 +300,000 | +17% | +$2.15M |
|
|
11
Gilead Sciences
GILD
$140B
| $13M | 2.01% | +205,000 | New | +$13M |
|
|
12
PTC Therapeutics
PTCT
$3.92B
| $10.5M | 1.62% | +310,000 | New | +$10.5M |
|
|
GWPH
13
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.51M | 1.32% | +74,000 | New | +$8.51M |
|
|
MLNX
14
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $8.43M | 1.3% | 76,875 +53,658 | +231% | +$5.88M |
|
15
Nice
NICE
$8.73B
| $8.22M | 1.27% | 57,193 +55,422 | +3,129% | +$7.97M |
|
|
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.11M | 1.25% | 565,000 +250,358 | +80% | +$3.59M |
|
17
UroGen Pharma
URGN
$900M
| $8M | 1.24% | 335,817 +27,440 | +9% | +$654K |
|
18
Rocket Pharmaceuticals
RCKT
$354M
| $7.69M | 1.19% | 660,000 +350,000 | +113% | +$4.08M |
|
19
Caesarstone
CSTE
$49.1M
| $7.67M | 1.18% | 461,509 -76,807 | -14% | -$1.28M |
|
20
Microsoft
MSFT
$3.77T
| $7.47M | 1.15% | 53,741 | – | – |
|
21
Stoke Therapeutics
STOK
$1.08B
| $7.38M | 1.14% | 346,380 -4,564 | -1% | -$97.3K |
|
22
Ascendis Pharma
ASND
$11.8B
| $7.11M | 1.1% | 73,773 | – | – |
|
23
uniQure
QURE
$896M
| $6.99M | 1.08% | 177,500 +117,351 | +195% | +$4.62M |
|
|
PTLA
24
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.97M | 1.08% | +260,000 | New | +$6.97M |
|
25
Fiserv
FI
$75.1B
| $6.97M | 1.08% | 67,279 +26,914 | +67% | +$2.79M |
|